Tomohiko Harada

Amiselimod, a novel sphingosine 1‐phosphate receptor‐1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk

Kunio Sugahara, Yasuhiro Maeda, Kyoko Shimano et al. · British Journal of Pharmacology · 2016 · 83 citations · Full text

Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial

Ludwig Kappos, Douglas L. Arnold, Amit Bar‐Or et al. · The Lancet Neurology · 2016 · 56 citations

Placebo-controlled Phase 2, Neurological Disorder, Medicine +8

Bupivacaine Extended Release Liposome Injection Does Not Prolong QTc Interval in a Thorough QT/QTc Study in Healthy Volunteers

Asif Naseem, Tomohiko Harada, Duolao Wang et al. · The Journal of Clinical Pharmacology · 2011 · 40 citations

Prolong Qtc Interval, Pain Medicine, Healthy Volunteers +6

Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel‐group, phase I study in healthy subjects

Tomohiko Harada, Darren Wilbraham, Guillemette de La Borderie et al. · British Journal of Clinical Pharmacology · 2016 · 35 citations · Full text

Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers

Jörg Täubel, Asif Naseem, Tomohiko Harada et al. · British Journal of Clinical Pharmacology · 2009 · 34 citations · Full text